Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency

Journal of Nuclear Medicine

Volumn 39, Issue 10, 1998, Pages 1681-1684

  Hwang, Eui Hyo ^a   Taki, Junichi ^b   Yasue, Shizuka ^b   Fujimoto, Manabu ^b   Taniguchi, Masayuki ^b   Matsunari, Ichiro ^b   Nakajima, Kenichi ^b   Shiobara, Shintaro ^b   Ikeda, Takayuki ^b   Tonami, Norihisa ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

15 (p iodophenyl) 3 (R,S) methyl pentadecanoic acid; CD36 deficiency; Family

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; CD36 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY ACID TRANSPORT; FLOW CYTOMETRY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNE DEFICIENCY; MONOCYTE; PRIORITY JOURNAL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE;

ADULT; AGED; ANTIGENS, CD36; BLOOD PLATELETS; FATTY ACIDS; FEMALE; HEART; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MIDDLE AGED; MONOCYTES; MYOCARDIUM; PLATELET MEMBRANE GLYCOPROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031714738     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Knapp FF Jr, Amburose KR, Goodman MM. New radioiodinated methyl-branched fatty acids for cardiac studies. Eur J Nucl Med 1986;12(suppl):S39-S44.
2. Tamaki N, Kawamoto M, Yonekura Y, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid. J Nucl Med 1992;33:659-667.
3. Saito T, Yasuda T, Gold HK, et al. Differentiation of regional perfusion and fatty acid uptake in zones of myocardial injury. Nucl Med Commun 1991;12:663-675.
4. Kurata C, Tawarahara K, Taguchi T, et al. Myocardial emission computed tomography with iodine-123-labeled beta methyl branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med 1992;33:6-13.
5. 201Tl. Nucl Med Commun 1993;14:181-188.
6. Takeishi Y, Chiba J, Abe S, Tonooka I, Komatani A, Tomoike H. Heterogeneous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy. Eur J Nucl Med 1992;19:775-782.
7. 121I-beta-methyl-iodophenyl pentadecanoic acid. Eur J Nucl Med 1994;21:283-291.
8. Nakajima K, Shimizu K, Taki J, et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med 1995;36:1934-1940.
9. Taki J, Nakajima K, Matsunari I, Bunko H, Takada S, Tonami N. Impairment of regional fatty acid uptake in relation to wall motion and thallium-201 uptake in ischemic but viable myocardium: assessment with iodine-123-labelled beta-methyl-branched fatty acid. Eur J Nucl Med 1995;22:1385-1392.
10. Matsunari I, Saga T, Taki J, et al. Kinetics of iodine-123-BMIPP in patients with prior myocardial infarction: assessment with dynamic rest and stress images compared with stress thallium-201 SPECT. J Nucl Med 1994;35:1279-1285.
11. Taki J, Nakajima K, Matsunari I, et al. Assessment of improvement of myocardial fatty acid uptake and function after revascularization using iodine-123-BMIPP. J Nucl Med 1997;38:1503-1510.
12. Hwang EH, Yamashita A, Takemori H, et al. Absent myocardial iodine-123 BMIPP uptake in a family. Ann Nucl Med 1996;10:445-448.
13. Kudoh T, Tamaki N, Magata Y, et al. Metabolism substrate with negative myocardial uptake of iodine-123-BMIPP. J Nucl Med 1997;38:548-553.
14. Kurata C, Wakabayashi Y, Shouda S, et al. Influence of blood substrate levels on myocardial kinetics of iodine-123-BMIPP. J Nucl Med 1997;38:1079-1084.
15. Tanaka T, Sohmiya K, Kawamura K. Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? J Mol Cell Cardiol 1997;29:121-127.
16. 123I-BMIPP myocardial accumulation with Type I CD36 deficiency. Jpn J Nucl Med 1997;34:481-486.
17. Glatz JF, Van der Vusse GJ. Intracellular transport of lipids. Mol Cell Biochem 1989;88:37-44.
18. Sorrentino D, Stump D, Potter B, et al. Oleate uptake by cardiac myocyte is carrier mediated and involves a 40-kD plasma membrane fatty acid binding protein similar to that in liver, adipose tissue, and gut. J Clin Invest 1988;82:928-935.
19. Stremmel W. Fatty acid uptake by isolated rat heart myocytes represents a carrier-mediated transport process. J Clin Invest 1988;81:844-852.
20. Vyska K, Meyer W, Stremmel W, et al. Fatty acid uptake in normal human myocardium. Circ Res 1991;69:857-870.
21. Abmurad NA, El-Maghrabi MR, Amri E-Z, Lopez E, Grimaldi PA. Cloning of rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. J Biol Chem 1993;268: 17665-17668.
22. Tanaka T, Kawamura K. Isolation of myocardial membrane long-chain fatty acid-binding protein: homology with a rat membrane protein implicated in the binding or transport of long-chain fatty acids. J Mol Cell Cardiol 1995;27:1613-1622.
23. Van Nieuwenhoven FA, Verstijnen CPHJ, Abumrad NA, et al. Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem Biophys Res Commun 1995;207:747-752.
24. Tandon NN, Kralisz U, Jamieson GA. Identification on glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989;264:7576-7583.
25. Asch AS, Barnwell J, Silverstein RL, Nachman RL. Isolation of the thrombospondine membrane receptor. J Clin Invest 1987;79:1054-1061.
26. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidised low density lipoprotein. J Biol Chem 1993;268:11811-11816.
27. Greenwalt DE, Scheck SH, Rhinehart-Jones T. Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest 1995;96:1382-1388.
28. Ikeda H, Mitani T, Ohnuma M, et al. A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989;57:213-217.
29. Yamamoto N, Ikeda H, Tandon NN, et al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable glycoprotein IV (CD36). Blood 1990;76:1698-1703.
30. Yamamoto N, Akamatsu N, Sakuraba H, Yamazaki H, Tanoue K. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (Type I) or the presence (Type II) of glycoprotein IV on monocytes. Blood 1994;83:392-397.
31. Kashiwagi H, Tomiyama Y, Nozaki S, et al. A single nucleotide insertion in codon 317 of the CD36 gene leads to CD36 deficiency. Arterioscler Thromb Vasc Biol 1996;16:1026-1032.
32. Kashiwagi H, Tomiyama Y, Honda S, et al. Molecular basis of CD36 deficiency. J Clin Invest 1995;95:1040-1046.
33. Kashiwagi H, Tomiyama Y, Kosugi S, et al. Identification of molecular defects in a subject with Type I CD36 deficiency. Blood 1994;83:3545-3552.
34. Fujibayashi Y, Yonekura Y, Takemura Y, et al. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S) methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 1990;31:1818-1822.
35. Fujibayashi Y, Nohara R, Hosokawa R, et, al. Metabolism and kinetics of iodine-123-BMIPP in canine myocardium. J Nucl Med 1996;37:757-761.
36. Nohara R, Okuda K, Ogino M, et, al. Evaluation of myocardial viability with iodine-123-BMIPP in a canine model. J Nucl Med 1996;37:1403-1407.